Skip to main content

Table 1 Key characteristics of the study population

From: Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

  Epoetin-ß
(n = 68)
Placebo
(n = 70)
Age, mean y (±SD) 59.1 (13.0) 62.1 (12.3)
Women, n(%) 12 (18) 18 (26)
Body mass index, mean (±SD) 28 (4) 27 (4)
Diabetes, n(%) 11 (16) 10 (14)
Current smoker, n(%) 29 (43) 30 (43)
Multivessel disease, n(%) 42 (62) 50 (71)
Angiographic LVEF, mean % (±SD) 46 (8) 46 (8)
Infarct related coronary artery, n(%)
 LAD 34 (50) 31 (44)
 RCA 19 (33.9) 18 (31.0)
 LCX 7 (12.5) 12 (20.7)
 LMCA 0 1 (1)
Initial TIMI flow grade, n(%)
 0 35 (52) 41 (59)
 1 11 (16) 11 (14)
 2 20 (29) 15 (21)
 3 2 (3) 4 (6)
Final TIMI flow grade, n(%)
 1 0 1 (1)
 2 5 (7) 6 (9)
 3 63 (93) 63 (90)
Type of intervention, n(%)
 Bare metal stent 3 (4) 3 (4)
 Drug-eluting stent 63 (93) 66 (95)
 Balloon angioplasty 2 (3) 1 (1)
Creatine kinase-MB max, U/L (range) 201 (121–450) 213 (124–312)
Symtom onset to PCI, min (range) 252 (175–413) 253 (165–457)
Hemoglobin max, mean g/dl (±SD) 14.8 (1.6) 15 (1.3)